FDA Approved: OFEV — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for OFEV (nintedanib) filed by Boehringer Ingelheim Pharmaceuticals, Inc., expanding its approved uses.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosing Interstitial Lung Disease
• Idiopathic Pulmonary Fibrosis
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• OFEV (Nintedanib)

Snippet

SUPPL AP for OFEV (NINTEDANIB)